Patent number: 9981919
Abstract: This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; substituted C1-6alkyloxyC1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(?O)pR6, —NH—S(?O)pR6, —C(?O)R6, —NHC(?O)H, —C(?O)NHNH2, —NHC(?O)R6, —C(?NH)R6 or a 5-membered heterocycle; X1 is —NR5—, —NH—NH—, —N?N—, —O—, —C(?O)—, C1-4alkanediyl,
Type:
Grant
Filed:
July 20, 2017
Date of Patent:
May 29, 2018
Assignee:
Janssen Pharmaceutical N.V.
Inventors:
Jérôme Emile Georges Guillemont, Patrice Palandjian, Marc René de Jonge, Lucien Maria Henricus Koymans, Hendrik Maarten Vinkers, Frederik Frans Desiré Daeyaert, Jan Heeres, Koen Jeanne Alfons Van Aken, Paulus Joannes Lewi, Paul Adriaan Jan Janssen
Publication number: 20180021361
Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
Type:
Application
Filed:
July 21, 2017
Publication date:
January 25, 2018
Applicants:
JANSSEN PHARMACEUTICALS, INC., ACHILLION PHARMACEUTICALS, INC.
Inventors:
Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
Publication number: 20180021360
Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
Type:
Application
Filed:
July 21, 2017
Publication date:
January 25, 2018
Applicants:
Janssen Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc.
Inventors:
Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke